Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sulindac for Reducing Breast Density in Postmenopausal Women at Risk of Breast Cancer
NCT04542135Phase 2Completed
- Sponsor
- Alison Stopeck
- Start
- Nov 2020
- Primary completion
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in breast cancer comparing Sulindac with Placebo (2 arms). Primary endpoint: Change in Percent Breast Density by MRI at 12 months. Started Nov 2020; status: completed.
02
Drugs
sulindac
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04542135.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04542135.